The Native Antigen Company (NAC) has released a highly purified cytomegalovirus (CMV) native antigen, which has been manufactured in response to the in vitro diagnostics (IVD) industry’s requirement for a cost-effective antigen that can demonstrate a high affinity for IgG and IgM. This latest antigen from NAC’s rapidly increasing portfolio also minimises cross-reactivity and lot-to-lot variation.
The laboratory business is under pressure to change. Market consolidation, standardisation, advanced automation, genomic testing, and the increase in point-of-care testing are driving major shifts in where, when, and how testing takes place. To not only survive, but to thrive, laboratories need a new generation of informatics solutions with...
Hyatt Regency, Vancouver, Canada
19-23 November, 2024
Hilton London Metropole, 255 Edgware Road, London, W2 1JU
11-12 December, 2024
Liverpool Arena and Convention Centre
31 March - 3 April, 2025
RAF Museum, Hendon, London NW9 5LL
15 May, 2025
ICC Ghent, Belgium
24-26 June, 2025
